Search

Becton Dickinson and Co

Lezárt

SzektorEgészségügy

183.41 0.86

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

180.71

Maximum

183.72

Fő mutatók

By Trading Economics

Bevétel

759M

449M

Értékesítés

269M

5B

P/E

Szektor átlag

30.601

57.002

Egy részvényre jutó nyereség

3.23

Osztalékhozam

2.37

Profit margin

9.011

Munkavállalók

72,000

EBITDA

-23M

686M

Ajánlások

By TipRanks

Ajánlások

Vétel

12 hónapos előrejelzés

+4.58% upside

Osztalékok

By Acuity

Osztalékhozam

Szektor átlag

2.37%

2.22%

Következő eredményjelentés

2026. nov. 5.

Következő osztalékfizetési dátum

2026. szept. 30.

Következő korábbi osztalék dátum

2026. szept. 9.

Piaci statisztika

By TradingEconomics

Piaci kapitalizáció

3.3B

49B

Előző nyitás

182.55

Előző zárás

183.41

Hangulat hírek alapján

By Acuity

21%

79%

67 / 340 Rangsor szerint Healthcare

Becton Dickinson and Co Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. aug. 14. 19:36 UTC

Becton Dickinson is trading higher today, despite a reported decline in retail sales for July that raised concerns about consumer demand.

2026. aug. 13. 22:01 UTC

Becton Dickinson shares are lower in after-market hours, continuing a decline from Thursday's close amid overall weakness in after-hours trading.

2026. aug. 12. 23:46 UTC

Event

Becton Dickinson announced successful enrollment completion in the PREVENT clinical trial for Phasix™ Mesh. Shares remain roughly flat in after-market trading.

2026. aug. 11. 22:26 UTC

Becton Dickinson is trading lower in after-market hours, reversing an initial gain. No specific news was identified to explain this price movement.

2026. aug. 10. 19:43 UTC

News

Becton Dickinson reports EPS of $3.23, exceeding estimates, and updates fiscal 2026 guidance, driving shares higher amid strong health care equipment sector gains.

2026. aug. 7. 21:11 UTC

News

Citigroup maintained its Buy rating on Becton Dickinson and raised its price target to $204, contributing to the stock's higher after-market trading.

2026. aug. 6. 23:01 UTC

Becton Dickinson and Co shares are higher in after-market hours, continuing a trend of three consecutive daily gains and remaining above the 20-day moving average.

2026. aug. 5. 19:46 UTC

Becton Dickinson shares are lower today amid broader market declines influenced by ADP's report on private sector job growth miss for July.

2026. aug. 4. 23:16 UTC

Becton Dickinson shares higher in after-market trading, reflecting positive market sentiment amid falling crude oil prices and expectations of reduced inflationary pressures.

2026. aug. 3. 22:51 UTC

Becton Dickinson shares are lower in after-market trading, influenced by a significant downturn in the Health Care Equipment sub-sector.

2026. júl. 31. 19:46 UTC

Becton Dickinson is higher today, showing resilience amid rising bond yields and inflation concerns. The stock remains above its 20-day moving average.

2026. júl. 30. 22:51 UTC

Becton Dickinson and Co shares are lower in after-hours trading, reflecting broader weakness in the Health Care Equipment sub-sector.

2026. júl. 29. 23:56 UTC

Becton Dickinson and Co shares are higher in after-market hours, maintaining momentum from Wednesday's close amid uncertainty over future interest rate decisions.

2026. júl. 28. 20:02 UTC

News

UBS initiated coverage of Becton Dickinson with a Buy rating and $190 price target, contributing to the stock's upward movement this week.

2026. júl. 27. 20:06 UTC

Becton Dickinson shares are higher, reflecting strength near the upper end of their one-month range amid falling oil prices and declining Treasury yields.

2026. júl. 24. 19:26 UTC

Becton Dickinson and Co is trading higher, supported by gains in the Health Care Equipment sub-sector and maintaining a position above its 20-day moving average.

2026. júl. 23. 19:56 UTC

Becton Dickinson shares are lower, extending a five-session decline amid ongoing market concerns over corporate earnings and inflation pressures from rising oil prices.

2026. júl. 21. 19:36 UTC

Becton Dickinson is trading lower today, extending a trend of three consecutive daily declines. No specific news was identified to explain the movement.

2026. júl. 20. 20:14 UTC

Becton Dickinson remains roughly flat in after-market trading, positioned 1.12% above its 20-day moving average, but has declined for three consecutive sessions.

Társak összehasonlítása

Árváltozás

Becton Dickinson and Co Előrejelzés

Célár

By TipRanks

4.58% elmozdulás felfelé

12 hónapos előrejelzés

Átlag 191.8 USD  4.58%

Magas 210 USD

Alacsony 175 USD

10 Wall Street elemző 12 hónapos célárain alapulva a(z)Becton Dickinson and Co termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Vétel

10 ratings

5

Vétel

5

Tartás

0

Eladás

Hangulat

By Acuity

67 / 340 Rangsor szerint Egészségügy

Hangulat hírek alapján

Nagyon erős bullish bizonyíték

Volatilitás

Átlag alatti

Hírmennyiség (RCV)

Átlag alatti

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

$

Rólunk Becton Dickinson and Co

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.
help-icon Live chat